MARKET

ABIO

ABIO

ARCA BIOPHARMA
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.34
+0.04
+0.75%
Closed 16:00 12/09 EST
OPEN
5.35
PREV CLOSE
5.30
HIGH
5.60
LOW
5.24
VOLUME
38.74K
TURNOVER
--
52 WEEK HIGH
20.45
52 WEEK LOW
4.725
MARKET CAP
8.51M
P/E (TTM)
-0.9404
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of ABIO and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

ABIO News

  • ARCA biopharma EPS beats by $0.54
  • seekingalpha.11/07 03:23
  • ARCA biopharma Q3 EPS $(0.76) Up From $(2.06) YoY
  • Benzinga.11/06 21:29
  • ARCA Biopharma Announces Third Quarter 2019 Financial Results and Provides Corporate Update
  • GlobeNewswire.11/06 21:10
  • Is ARCA biopharma (NASDAQ:ABIO) In A Good Position To Invest In Growth?
  • Simply Wall St..11/03 13:47

More

Industry

Pharmaceuticals
+0.14%
Pharmaceuticals & Medical Research
+0.23%

Hot Stocks

Name
Price
%Change

About ABIO

ARCA biopharma, Inc. (ARCA) is a biopharmaceutical company. The Company is principally focused on developing genetically-targeted therapies for cardiovascular diseases. The Company's lead product candidate is Gencaro (bucindolol hydrochloride), a beta-blocker and mild vasodilator that the Company is evaluating in a clinical trial for the treatment of atrial fibrillation (AF) in patients with heart failure with reduced left ventricular ejection fraction (HFREF). Gencaro is considered part of the beta-blocker class of compounds because of its property of blocking both beta-1 and beta-2, receptors in the heart. The blocking of these receptors prevents the receptor from binding with other molecules, primarily the neurotransmitter norepinephrine (NE), which activate these receptors. The Company is conducting a Phase IIB/III clinical trial of Gencaro, known as GENETIC-AF.
More

Webull offers Arca Biopharma Inc (ABIO) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.